Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY

Benzinga Newsdesk www.benzinga.com Negative 66.6%

Neg 66.6% Neu 0% Pos 0%

Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in sales this quarter. This is a 34.62 percent increase over sales of $119.802 million the same period last year.